Blood component potentiation of lytic protein anti-bacterial activity and methods and uses thereof
AssigneeContrafect Corporation
InventorRaymond SCHUCH
Life of this patent
Estimating the term…
Abstract
The present invention provides methods, assays, compositions, formulations, and constructs, particularly lytic peptide constructs, which relate to and are based on the activity and use of blood components, particularly serum albumin and lysozyme, and their activity and use to enhance or synergize with the bacterial killing effect of anti-bacterial lytic proteins and peptides.
Claims39
A composition for enhanced or synergistic killing of Gram-positive bacteria, the composition comprising an isolated lysin polypeptide having an SH3 type binding domain and one or more blood component protein, wherein the one or more blood component proteins comprise serum albumin, lysozyme or fragments thereof, wherein said fragments thereof demonstrate activity of the serum albumin or lysozyme protein with regard to enhancement or synergistic killing of the Gram-positive bacteria.
A method of killing or reducing a population of Gram-positive bacteria comprising contacting the Gram-positive bacteria with a composition comprising an amount of an isolated lysin polypeptide effective to kill the Gram-positive bacteria, the isolated lysin polypeptide having an SH3-type binding domain, and one or more blood component proteins selected from serum albumin, lysozyme and fragments thereof.
A method for treating an antibiotic-resistant Staphylococcus aureus infection in a human comprising administering to a human having an antibiotic-resistant Staphylococcus aureus infection, an effective amount of a composition comprising an amount of an isolated lysin polypeptide having an SH3-type binding domain and capable of killing a Gram-positive bacteria, and human lysozyme.
A chimeric or fusion polypeptide comprising a lysin-derived SH3-type bacterial binding domain and human serum albumin or a fragment thereof capable of binding Gram-positive bacteria.
A chimeric or fusion polypeptide comprising a lysin-derived SH3-type bacterial binding domain and human lysozyme or a fragment thereof capable of lysing Gram-positive bacteria.
A method for enhancing the antibacterial activity of an antibacterial agent or peptide comprising administering the agent or peptide in combination with a lysin polypeptide having an SH3-type binding domain and human serum albumin or a fragment thereof capable of binding Gram-positive bacteria.
A method for enhancing the antibacterial activity of an antibacterial agent or peptide comprising administering the agent or peptide in combination with a lysin polypeptide having an SH3-type binding domain and lysozyme or a fragment thereof capable of lysing Gram-positive bacteria.
A method for susceptibility testing of Gram-positive bacteria comprising evaluating an antibacterial peptide in broth, assay medium or solution supplemented with serum albumin.
Dependencies are inferred from the claim text.